{
  "variants": [
    {
      "gene": "SNCA",
      "variant": "E46K",
      "functional_evidence": {
        "effect": "Increased fibrillization propensity compared to wild-type, but less than A53T. Alters polymer ultrastructure.",
        "controls": {
          "wild_type": true,
          "pathogenic_control": true,
          "benign_control": false
        },
        "replicates": {
          "explicitly_stated": false
        },
        "assay_validity": {
          "historically_accepted": true,
          "prior_validation": true
        },
        "odds_path": {
          "calculated": false
        }
      },
      "acmg_assessment": {
        "step_1": {
          "disease_mechanism_defined": true,
          "justification": "Mutations in α-synuclein (SNCA) are directly linked to amyloid fibril formation, a core pathological mechanism in Parkinson's disease."
        },
        "step_2": {
          "assay_applicability": true,
          "justification": "Functional assays (fibrillization propensity, polymer ultrastructure) are well-established models for amyloid-related diseases."
        },
        "step_3": {
          "substep_3a": {
            "controls_and_replicates": false,
            "justification": "The paper does not explicitly state the use of multiple replicates or detailed controls (e.g., wild-type vs. mutant comparisons)."
          },
          "substep_3b": {
            "assay_validity": true,
            "justification": "Fibrillization assays are broadly accepted in amyloid disease research and validated in prior studies."
          },
          "substep_3c": {
            "variant_controls": false,
            "justification": "No explicit mention of known pathogenic/benign variants used as controls in this study."
          }
        },
        "step_4": {
          "substep_4a": {
            "statistical_analysis": false,
            "justification": "No OddsPath calculation or robust statistical metrics (e.g., p-values, confidence intervals) are explicitly reported."
          },
          "substep_4b": {
            "control_count": 2,
            "justification": "Only two variants (E46K and A53T) are compared in this study, with no explicit mention of additional controls."
          },
          "substep_4c": {
            "odds_path_inference": false,
            "justification": "No OddsPath value or direct statistical inference is provided for E46K."
          }
        },
        "final_strength": "PS3_supporting",
        "justification": "The assay is historically accepted (fibrillization studies), and the functional effect (increased fibrillization) is directly observed, even without explicit controls or replicates."
      }
    },
    {
      "gene": "SNCA",
      "variant": "A53T",
      "functional_evidence": {
        "effect": "Greater fibrillization propensity than E46K. Alters polymer ultrastructure and mature amyloid properties.",
        "controls": {
          "wild_type": true,
          "pathogenic_control": true,
          "benign_control": false
        },
        "replicates": {
          "explicitly_stated": false
        },
        "assay_validity": {
          "historically_accepted": true,
          "prior_validation": true
        },
        "odds_path": {
          "calculated": false
        }
      },
      "acmg_assessment": {
        "step_1": {
          "disease_mechanism_defined": true,
          "justification": "A53T is a well-known pathogenic variant in Parkinson's disease, directly linked to α-synuclein aggregation."
        },
        "step_2": {
          "assay_applicability": true,
          "justification": "Same as E46K; fibrillization assays are valid for amyloid disease research."
        },
        "step_3": {
          "substep_3a": {
            "controls_and_replicates": false,
            "justification": "No explicit mention of replicates or controls in the paper."
          },
          "substep_3b": {
            "assay_validity": true,
            "justification": "Fibrillization assays are broadly accepted and validated."
          },
          "substep_3c": {
            "variant_controls": false,
            "justification": "No explicit mention of known pathogenic/benign variants used as controls in this study."
          }
        },
        "step_4": {
          "substep_4a": {
            "statistical_analysis": false,
            "justification": "No OddsPath calculation or robust statistical metrics are explicitly reported."
          },
          "substep_4b": {
            "control_count": 2,
            "justification": "Only two variants (E46K and A53T) are compared in this study, with no explicit mention of additional controls."
          },
          "substep_4c": {
            "odds_path_inference": false,
            "justification": "No OddsPath value or direct statistical inference is provided for A53T."
          }
        },
        "final_strength": "PS3_moderate",
        "justification": "A53T is a well-established pathogenic variant in Parkinson's disease. The paper's comparison to E46K (a weaker effect) supports its stronger functional impact, even without explicit controls or replicates."
      }
    }
  ]
}